Germany shifts to fixed drug discounts after industry backlash

Germany is dropping a plan for variable pharmaceutical discounts and moving to fixed markdowns after fierce industry pushback over uncertainty for manufacturers and investors. The shift keeps Berlin on course to squeeze drug costs, but it also signals a softer political line toward one of Europe’s most powerful health-care industries. The central test now is whether the simpler pricing model can lower spending without unsettling supply or investment.

The original rebate idea sat inside a ministerial draft dated April 16, 2026, designed to stabilize statutory health insurance contribution rates from 2027. That draft was built around a nearly €10 billion deficit in the German statutory health insurance system in 2024 and a financing gap that policy summaries say could reach about €40 billion by 2030. Drug-spending cuts were expected to deliver €1.9 billion in savings next year, while the broader reform was described as a way to generate €16.3 billion in 2027.

Industry opposition centered on the shape of the discount itself. The abandoned concept was described in commentary as a variable, uncapped manufacturer rebate tied to expenditure growth, with some analyses projecting that the effective rate could climb to about 20% by 2030 if Berlin had kept the formula intact. For drugmakers, that created a moving target for pricing, reimbursement and long-term planning in Germany, one of Europe’s most influential medicines markets.

The pressure became more visible in May when Pfizer chief executive Albert Bourla warned Chancellor Friedrich Merz that the reforms put the predictability needed for long-term investment in doubt. FiercePharma reported that Pfizer was reviewing the timing, scope and priorities of planned investments in Germany, and that two global drugmakers had already cut planned investments there. That warning echoed a wider complaint from the sector: that volatile pricing rules can affect not only profits, but also research decisions, manufacturing commitments and launch strategies.

Germany’s health ministry had not commented publicly on the reported shift. For patients and insurers, fixed markdowns may offer a clearer route to savings than a dynamic rebate formula; for pharmaceutical companies, the change suggests Berlin is trying to preserve access to investment capital while still forcing the industry to help close a widening public-finance gap.